Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis (MS)~* Relapsing MS (RMS)~* At least 1 appearance of a new neurological abnormality or worsening of pre-existing neurological abnormality during the previous 2 years prior to Screening AND an MRI activity (Gd-enhancing T1 lesions or new or enlarging T2 lesions) in brain during the previous 1 year prior to randomization~* EDSS score of 0 to 5.5~Exclusion Criteria:~* Primary progressive MS or SPMS without disease activity~* Patients with an active chronic disease of the immune system other than MS~* Patients at risk of developing or having reactivation of hepatitis~* Patients with active systemic infections or with neurological findings consistent with PML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- OMB 20 mg (Type: EXPERIMENTAL): Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core

Based on this trial design, predict the completion outcome and termination type (if applicable).